A proof of concept for the validity of targeting Hsp40s for neurodegeneration therapy is provided by studies of the human Hsp40 chaperone HSJ1 whose overexpression in ALS mice model ameliorated the disease state. This evidence concerns the gene DNAJB2 and amyotrophic lateral sclerosis.